Drug Trial Radar · NCT07025369
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 25, 2025
Primary completion
Jan 1, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA positron emission tomography (PET)/computed tomography (CT) in patients with high risk or very high risk prostate cancer. PSMA PET/CT has become the standard of care in imaging for high-risk prostate cancer. However, a limitation of PSMA PET/CT is its ability to detect cancer that has spread to the lymph nodes. PSMA is a protein that is usually found on the surface of normal prostate cells but is found in higher amounts on prostate tumor cells. Studies have shown that expression of PSMA is regulated by androgens (male reproductive hormones). Relugolix binds to gonadotropin-releasing hormone receptors in the pituitary gland, which blocks the pituitary gland from making the hormones follicle-stimulating hormone and luteinizing hormone. This causes the testicles to stop making testosterone. Relugolix may stop the growth of tumor cells that need testosterone to grow. PSMA PET/CT is an imaging procedure that is used to help find prostate tumor cells in the body. For this procedure, a cell-targeting molecule linked to a radioactive substance (flotufolastat F 18 in this trial) is injected into the body and travels through the blood. It attaches to PSMA that is found on the surface of prostate tumor cells. PET/CT scanners detect high concentrations of the radioactive molecule and shows where the prostate tumor cells are in the body. Giving a short course of ADT with relugolix may increase PSMA expression to detect smaller areas of prostate cancer that were not previously detected.
Conditions
- Prostate Adenocarcinoma
- Stage IIC Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo PET/CT
Flotufolastat F-18 GalliumOther
Given flotufolastat F 18
Laparoscopic Radical Prostatectomy with RoboticsProcedure
Undergo robotic assisted radical prostatectomy
Pelvic LymphadenectomyProcedure
Undergo pelvic lymph node dissection
Positron Emission TomographyProcedure
Undergo PET/CT
RelugolixDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum standard uptake value (SUVmax) for pre and post androgen deprivation therapy (ADT) prostate-specific antigen (PSMA) positron emission tomography (PET)Time frame: Day 0 up to day 15
- Mean standard uptake value (SUVmean) for pre and post ADT PSMA PETTime frame: Day 0 up to day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.